Diagnostrix: Difference between revisions
Created from NHT member research |
Created with researched data |
||
| Line 1: | Line 1: | ||
{{ | {{DISPLAYTITLE:Diagnostrix}} | ||
|name=Diagnostrix | {{Infobox company | ||
| | | name = Diagnostrix AS | ||
| | | org_number = 925098787 | ||
| | | founded = 2020-03-19 | ||
|funding= | | employees = Not disclosed | ||
| | | address = Norway | ||
| industry = 72.100 – Biotechnology research | |||
| website = https://www.diagnostrix.no (limited access) | |||
| nht_category = Startup | |||
| description = Diagnostrix is focused on enabling early, non-invasive endometriosis diagnosis. The company is developing diagnostic technology to allow women to gain access to early diagnosis without invasive procedures. Mission: enabling women to take control of their health journey and prevent complications through early detection. | |||
| notes = No disclosed revenue or funding. Endometriosis diagnostics is a significant unmet need — affects ~10% of women of reproductive age globally. | |||
| related_companies = [[PicnicHealth]], [[NordicDx]], [[Norway Health Tech]] | |||
| categories = Norway Health Tech, Startups, Diagnostics, Women's Health | |||
| sources = https://www.diagnostrix.no; https://data.brreg.no/enhetsregisteret/api/enheter/925098787 | |||
}} | }} | ||
== | == About == | ||
Diagnostrix AS is a Norwegian biotechnology company focused on enabling early, non-invasive diagnosis of endometriosis. The company was founded in March 2020 and operates under the guiding philosophy: "Caring for our Women, Caring for our World." | |||
== | == Market Need == | ||
Endometriosis is a condition in which tissue similar to the lining of the uterus grows outside the uterus, causing pain, infertility, and other symptoms. Current diagnosis typically requires laparoscopic surgery, which is invasive and often delayed by 7-10 years on average from symptom onset to diagnosis. There is a significant unmet need for non-invasive diagnostic methods. | |||
[[Category: | == Technology == | ||
[[Category: | |||
Diagnostrix is developing non-invasive diagnostic technology to enable earlier endometriosis diagnosis without the need for invasive surgical procedures. The company aims to allow women to take control of their health journey and prevent complications through early detection. | |||
== References == | |||
<references/> | |||
[[Category:Norway Health Tech]] | |||
[[Category:Startups]] | |||
[[Category:Diagnostics]] | |||
[[Category:Women's Health]] | |||
Latest revision as of 20:01, 14 April 2026
About[edit]
Diagnostrix AS is a Norwegian biotechnology company focused on enabling early, non-invasive diagnosis of endometriosis. The company was founded in March 2020 and operates under the guiding philosophy: "Caring for our Women, Caring for our World."
Market Need[edit]
Endometriosis is a condition in which tissue similar to the lining of the uterus grows outside the uterus, causing pain, infertility, and other symptoms. Current diagnosis typically requires laparoscopic surgery, which is invasive and often delayed by 7-10 years on average from symptom onset to diagnosis. There is a significant unmet need for non-invasive diagnostic methods.
Technology[edit]
Diagnostrix is developing non-invasive diagnostic technology to enable earlier endometriosis diagnosis without the need for invasive surgical procedures. The company aims to allow women to take control of their health journey and prevent complications through early detection.